Please assess the completion status of the following clinical trial:

Trial Title: Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have provided written informed voluntary consent;~* Be able to speak, read, and understand English;~* Be males or females, of any race, between 18 and 80 years of age, inclusive;~* Have a body mass index (BMI) \>= 18 and \< 35 kg/m\^2;~* Be in good general health with no clinically relevant abnormalities based on the medical history, physical examination, clinical laboratory evaluations (hematology, clinical chemistry, and urinalysis), and 12 lead electrocardiogram;~* Be non-smokers for at least 5 years;~* If a female of child-bearing potential (I. e., have not undergone a hysterectomy or bilateral oophorectomy) or not post-menopausal (defined as no menses for at least 12 months), agree to use 2 forms of acceptable birth control; or if a male, they and/or their partner of child-bearing potential agree to use 2 forms of acceptable birth control;~* Be able to communicate effectively with the Investigator and other study center personnel and agree to comply with the study procedures and restrictions.~* Subjects with chronic cough must have treatment-refractory chronic cough for at least one year, with no objective evidence of an underlying trigger (e. g., asthma)~Exclusion Criteria:~* History of upper respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Baseline Visit (Day 0);~* Have acute worsening of asthma;~* Do not cough during the ATP or Capsaicin or Citric acid challenge at Screening or only cough twice at the two highest concentrations of the test solution;~* History of concurrent malignancy or recurrence of malignancy within 2 years prior to Screening (not including subjects with \<3 excised basal cell carcinomas);~* History of a diagnosis of drug or alcohol dependency or abuse within approximately the last 3 years;~* Clinically significant abnormal electrocardiogram (ECG) at Screening;~* Significantly abnormal laboratory tests at Screening;~* Pregnant or breastfeeding;~* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the Investigator or Sponsor, would make the subject inappropriate for entry into this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Placebo then gefapixant 100 mg/Healthy (Sequence A) (Type: EXPERIMENTAL): Healthy participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 \& 2.
- Gefapixant 100 mg then placebo/Healthy (Sequence B) (Type: EXPERIMENTAL): Healthy participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 \& 2.
- Placebo then gefapixant 100 mg/Chronic Cough (Sequence A) (Type: EXPERIMENTAL): Chronic Cough participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 \& 2.
- Gefapixant 100 mg then placebo/Chronic Cough (Sequence B) (Type: EXPERIMENTAL): Chronic Cough participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 \& 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).